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Abstract 
COVID-19 patients show varying severity of the disease ranging from asymptomatic to requiring 
intensive care. Although a number of monoclonal antibodies against SARS-CoV-2 have been 
identified, we still lack an understanding of the overall landscape of B-cell receptor (BCR) repertoires 
in COVID-19 patients. Here, we used high-throughput sequencing of BCR repertoires collected over 
multiple time points during an infection to characterize statistical and dynamical signatures of the B-
cell response to SARS-CoV-2 in 19 patients with different disease severities. Based on principled 
statistical approaches, we determined differential sequence features of BCRs associated with different 
disease severity. We identified 34 significantly expanded rare clonal lineages shared among patients 
as candidates for a specific response to SARS-CoV-2. Moreover, we identified natural emergence of 
a BCR with cross-reactivity to SARS-CoV and SARS-CoV-2 in a number of patients. Overall, our 
results provide important insights for development of rational therapies and vaccines against COVID-
19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The novel coronavirus SARS-CoV-2, which causes the severe respiratory disease COVID-19, has now 
spread to 216 countries and caused more than ten million infections with a mortality rate around 5% 
(WHO, 2020). COVID-19 patients show varying disease severity ranging from asymptomatic to 
requiring intensive care. While epidemiological and clinical data report that many factors such as age, 
gender, genetic background, and preexisting conditions are associated with disease severity, host 
immunity against the virus infection is the crucial component of controlling disease progression 
(Ellinghaus et al., 2020; Guan et al., 2020; McKechnie and Blish, 2020; Vabret et al., 2020; Wu et al., 
2020a). Shedding light on signatures of a protective immune response against SARS-CoV-2 infections 
can help understand the nature of COVID-19 and guide the therapeutic developments as well as 
vaccine design and assessment. 
 
Adaptive immunity is considered as one of the core protective mechanisms in humans against 
infectious diseases. A vast diversity of surface receptors on B- and T-cells enables us to recognize and 
counter new or repeated invasions from a multitude of pathogens (Janeway et al., 2005; Nielsen and 
Boyd, 2018). In particular, antibodies produced by B-cells can provide long-lasting protection against 
specific pathogens through neutralization or other antibody-mediated immune mechanisms (Janeway 
et al., 2005). During the early phase of an infection, antigens of a pathogen are recognized by a group 
of naïve B-cells, which then undergo affinity maturation in a germinal center through somatic 
hypermutation and selection. The B-cell receptors (BCRs) of mature B-cells can strongly react to 
infecting antigens, resulting in B-cell stimulation, clonal expansion, and ultimately secretion of high 
affinity antibodies in the blood (Burnet, 1959; Burnet, 1960; Cyster and Allen, 2019). The specificity 
of a BCR is determined by a number of features such as V-, (D-) or J-gene usage, length and sequence 
composition of the HCDR3 region. It has been found that SARS-CoV-2-specific IgG antibodies can 
be detected in plasma samples of COVID-19 patients starting from the first week after the onset of 
symptoms (Perera et al., 2020). These antibodies bind to different antigens including spike protein and 
nucleoprotein as well as other structural or non-structural proteins (Hachim et al., 2020). In addition, 
multiple studies have isolated SARS-CoV-2-specific B-cells from COVID-19 patients and determined 
their germline origin (Brouwer et al., 2020; Cao et al., 2020; Chi et al., 2020; Ju et al., 2020; Liu et 
al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020a; Seydoux et al., 2020b; Wu 
et al., 2020b; Zost et al., 2020). However, we still lack a comprehensive view of the patients’ entire 
BCR repertoires during SARS-CoV-2 infections. 
 
Antibody repertoire sequencing has advanced our understanding of the diversity of adaptive immune 
repertoires and their response to pathogens (Boyd et al., 2009; Georgiou et al., 2014; Kreer et al., 2020; 
Robins, 2013). A few studies have performed BCR repertoire sequencing to characterize the statistical 
signatures of the immune response to SARS-CoV-2 (Galson et al., 2020; Nielsen et al., 2020; 
Schultheiß et al., 2020). However, these studies have limited data on the dynamics of BCR repertoires, 
which could otherwise provide significant insight into specific responses to the infection. In this study, 
we have established a principled statistical approach to study the statistics and dynamics of BCR 
repertoires and to characterize the immune responses in 19 COVID-19 patients with different disease 
severities. Importantly, by combining information from the statistics of sequence features in BCR 
repertoires, the expanding dynamics of clonal lineages during infection, and sharing of BCRs among 
COVID-19 patients, we identified 34 clonal lineages that are potential candidates for a response to 
SARS-CoV-2. Moreover, we identified cross-reactive responses to SARS-CoV in some of the 
COVID-19 patients and a natural emergence of a previously isolated SARS-reactive antibody (Pinto 
et al., 2020) in three patients. 
 
Results 
 
B-cell repertoires differ in receptor compositions across cohorts. We obtained total RNA from the 
PBMC isolated from 19 patients infected with SARS-CoV-2 and three healthy individuals (see 
Methods and Tables S1, S2 for details). The patients showed different severity of symptoms, forming 
three categories of infected cohorts: 2 patients with mild symptoms, 12 patients with moderate 
symptoms, and 5 patients with severe symptoms. Specimens from all patients, except patient 19, were 
collected over two or more time points during the course of the infection. The sampled time points for 
all patients are indicated in Fig. 1 and Tables S1. IgG heavy chains of B-cell repertoires were 
sequenced by next-generation sequencing, and the statistics of the collected BCR read data from each 
sample are shown in Table S1. Statistical models were applied to analyze the length of the HCDR3 
region, IGHV- or IGHJ-gene usage, and insertion/deletion patterns as well as the expansion of specific 
clonal lineages (Fig. 1). 
 
We first aimed to investigate whether cohorts with different disease severities can be distinguished by 
molecular features of their B-cell repertoires. Since sequence features of immune receptors (e.g. 
HCDR3 length, V- or J-gene usage, and insertion/deletion patterns) are often associated with their 
binding specificity, we used statistical methods to compare these features both at the level of clonal 
lineages, including the inferred receptor sequence of lineage progenitors (Figs. 2, S2), and unique 
sequences (Figs. S1, S2) in a repertoire. Lineage progenitors of IgG repertoires are closest to the 
ensemble of naïve receptors in the periphery. Features of lineage progenitors reflect receptor 
characteristics that are necessary for activating and forming a clonal lineage in response to an infection. 
Statistics of unique sequences in a repertoire, on the other hand, contain information about the size of 
the circulating lineages. Importantly, these two statistical ensembles are relatively robust to PCR 
amplification biases that directly impact read abundances (see Methods for error correction and 
processing of sequence reads). 
 
IGHV genes cover a large part of pathogen-engaging regions of BCRs, including the three 
complementarity-determining regions HCDR1, HCDR2, and a portion of HCDR3. Therefore, we 
investigated if there are any differences in V-gene usage across cohorts, which may indicate 
preferences relevant for response to a particular pathogen. We found that the variation in V-gene usage 
among individuals within each cohort was far larger than differences among cohorts (Fig. 2A). Data 
from unique sequences also indicated large background amplitudes due to vast differences in the sizes 
of lineages within a repertoire (Fig. S1). Similarly, IGHJ-gene usage was also comparable across 
different cohorts (Fig. S2). Our results suggest that the SARS-CoV-2 V-gene specific responses are 
highly individualized at the repertoire level. 
 
HCDR3 is part of the variable chain of B-cell receptors and is often a crucial region in determining 
specificity. Importantly, HCDR3 is highly variable in its sequence content and length due to insertion 
and deletion of sequence fragments at the VD and DJ junctions of the germline receptor. Therefore, 
differential characteristics of the HCDR3 sequence in BCR repertoires of different cohorts can signal 
preferences for sequence features specific to a class of antigens. We find that HCDR3s in COVID-19 
patients with moderate and severe symptoms are significantly longer than in the healthy control, both 
at the level of clonal lineages (Fig. 2B) and unique sequences in each repertoire (Fig. S1B). The 
difference between HCDR3s length in healthy individuals and patients with mild symptoms is 
insignificant (p-values for significance of these deviations are given in the corresponding Figure 
captions). Recent studies have also identified propensity for longer HCDR3s in BCR repertoires of 
COVID-19 patients (Galson et al., 2020; Nielsen et al., 2020; Schultheiß et al., 2020). We find that 
the longer HCDR3 length in patients with moderate and severe symptoms is primarily due to insertion 
of larger sequence fragments and also shorter deletions at the VD junction (Figs. 2C-D, S1C-D). 
Interestingly, the insertion/deletion patterns at the DJ junctions did not show a substantial difference 
across cohorts (Fig. S2C-F). 
 
Longer sequence insertions in HCDR3 can introduce more sequence diversity at the repertoire level. 
Quantifying sequence diversity of a B-cell repertoire, however, is very sensitive to the sampling depth 
in each individual. Despite progress in the quality of high-throughput repertoire sequencing (RepSeq) 
techniques, sequenced BCRs still present a highly under-sampled view of the entire repertoire. To 
characterize the diversity of repertoires and the statistics of sequence features that make up this 
diversity, we inferred principled models of repertoire generation and selection for the entry of 
receptors into the periphery (Methods) (Elhanati et al., 2014; Marcou et al., 2018). To do so, we first 
used data from unproductive B-cell receptors to infer the highly non-uniform baseline model that 
characterizes the probability 𝑃gen(σ) to generate a given receptor sequence (Elhanati et al., 2014; 
Marcou et al., 2018) (Fig. 1 and Methods). This baseline model reflects sequence biases in generating 
BCRs in the bone marrow. 
 
The functional, yet pathogen-naïve BCRs that enter the periphery experience selection through 
processes known as central tolerance (Janeway et al., 2005). In addition, the inferred progenitors of 
clonal lineages in the IgG repertoire have undergone antigen-dependent selection that led to expansion 
of their clonal lineage in response to an infection. These two levels of selection make sequence features 
of functional lineage progenitors distinct from the pool of unproductive BCRs that reflects biases of 
the generation process prior to any selection. To identify these distinguishing sequence features, we 
inferred a selection model for lineage progenitors (Methods). We characterized the probability to 
observe a clonal lineage ancestor in the periphery as 𝑃post(σ) ∼ 𝑃gen(σ)𝑒'(:features*((+), which deviates 
from the inferred generation probability of the receptor 𝑃gen(σ)	by selection factors 𝑞.(𝜎) (Isacchini 
et al., 2020a; Isacchini et al., 2020b; Sethna et al., 2020) . These selection factors 𝑞.(𝜎) depend on 
sequence features, including IGHV-gene and IGHJ-gene usages, HCDR3 length, and amino acid 
preferences at different positions in the HCDR3 (Methods) (Elhanati et al., 2014; Isacchini et al., 
2020a; Isacchini et al., 2020b; Marcou et al., 2018; Sethna et al., 2020).  
 
The distribution of the log-probability log34	𝑃post(σ) for the inferred progenitors of clonal lineages 
observed in individuals from different cohorts is shown in Fig. 3A. We find an overabundance of BCR 
lineages with progenitors that have a low probability of entering the periphery (i.e., a lower 𝑃post(σ)) 
in COVID-19 patients compared to healthy individuals (Fig. 3A). Moreover, we estimated the 
diversity of the repertoires in each cohort by evaluating the entropy of receptor sequences generated 
by the respective repertoire models (see Methods). In particular, diverse repertoires that contain B-cell 
lineages with rare receptors (i.e., those with a lower 𝑃post(σ)), should have larger entropies. Based on 
this analysis, we find that immune repertoires are more diverse in COVID-19 patients compared to 
healthy individuals (Fig. 3A and Methods). Specifically, the entropy (i.e., diversity) of BCR 
repertoires grew with severity of the disease, from 38.7 bits in the healthy cohort to 40.5 bits in the 
mild cohort, to 41.6 bits in the moderate cohort, and to 41.3 bits in the severe cohort (see Methods).  
 
Selection factors 𝑞.(𝜎) determine the deviation in preferences for different sequence features of 
BCRs in each cohort, including their HCDR3 length and composition, and IGHV-gene usages. A 
comparison of selection factors among cohorts can characterize their distinctive sequence features. 
Consistent with our previous analysis of lineage characteristics in Fig. 2A, we find that selection 
factors associated with V-gene usage are strongly correlated across cohorts (Fig. 3B). However, we 
find a weaker correlation for selection factors associated with preference for HCDR3 length between 
healthy individuals and the cohorts of COVID-19 patients (Fig. 3B), which is consistent with our 
observation in Fig. 2B. Moreover, there are only weak correlations for HCDR3 amino acid preferences 
between healthy individuals and the cohorts of COVID-19 patients (Fig. 3B). Interestingly, the 
HCDR3 composition was most distinct between patients with moderate symptoms and the healthy 
cohort, with 73% correlation for length and 65% correlation for amino acid preferences (Fig. 3B). The 
HCDR3 composition was most similar between patients with moderate and severe symptoms, with 
92% correlation for length and 89% correlation for amino acid preferences (Fig. 3B). Taken together, 
HCDR3 represents a molecular feature that is distinguishable among cohorts. 
 
Expansion of BCR clonal lineages over time as a proxy for response to SARS-CoV-2. Next, we 
examined the dynamics of BCR repertoires in the COVID-19 patients. The binding level (measured 
by OD450 in ELISA assays) of both IgM and IgG antibodies against the receptor-binding domain 
(RBD) or N-terminal domain (NTD) of SARS-CoV-2 increased in most of the COVID-19 patients in 
our study over the course of their infection (Figs. 4A, S3). We expected that the increase of OD450 
binding level is associated with activation of specific B-cells, resulting in an increase in mRNA 
production of the corresponding BCRs. Detecting expansion of specific clonal lineages is challenging 
due to subsampling of the repertoires. In fact, only a limited overlap of BCR lineages was found if we 
simply compared the data between different time points or between replicates of a repertoire sampled 
at the same time point (Fig. S4). To identify expanding clonal lineages, we examined lineages only in 
patients whose plasma showed an increase in binding level (OD450) to the RBD of SARS-CoV-2 and 
compared the sequence abundance of those lineages that appear in two or more time points (Figs. 4A, 
S3 and Methods). Using a hypothesis test with a false discovery rate of 7.5%, as determined by 
analyzing replicate data (Methods, Fig. S5), we detected significant expansion of clonal lineages 
within all investigated patients. The results reflect a dynamic repertoire in all patients, ranging from 
5% to 15% of lineages with significant expansion and large changes in sequence abundances over time 
(Figs. 4, S6). The expanding lineages had comparable HCDR3 length to the rest of the repertoire in 
COVID-19 patients (Fig. S6). Moreover, we observed expanding lineages to show V-gene preferences 
comparable to those of previously identified antibodies against SARS-CoV-2 (RBD). This includes 
the abundance of IGHV4-59, IGHV4-39, IGHV3-23, IGHV3-53, IGH3-66, IGHV2-5, and IGHV2-
70 (Brouwer et al., 2020; Ju et al., 2020; Pinto et al., 2020; Rogers et al., 2020). However, it should 
be noted that these preferences in V-gene usage among expanding lineages are comparable to the 
overall biases in V-gene usage within patients, and expanded lineages roughly make up 25% of 
lineages with a given V gene (Fig. 4C). Therefore, Our results suggest that the overall response to 
SARS-CoV-2 is not driven by only a specific class of IGHV gene. 
 
Sharing of BCRs among individuals. Despite the vast diversity of BCRs, we observe a significant 
number of identical progenitors of BCR clonal lineages among COVID-19 patients (Fig. 5) and among 
healthy individuals (Fig. S7). Previous work has also identified sharing of BCRs among COVID-19 
patients, which was interpreted by the authors as evidence for large-scale convergence of immune 
responses (Galson et al., 2020; Nielsen et al., 2020; Schultheiß et al., 2020). Although BCR sharing 
can be due to convergent response to common antigens, it can also arise from convergent 
recombination leading to the same receptor sequence (Elhanati et al., 2018; Pogorelyy et al., 2018a) 
or simply from experimental biases. Therefore, it is imperative to formulate a null statistical model to 
identify the outliers among shared BCRs as candidates for common responses to antigens. Convergent 
recombination defines a null expectation for the amount of sharing within a cohort based on only the 
underlying biases for receptor generation within a repertoire (Elhanati et al., 2018; Pogorelyy et al., 
2018a) (Methods). Intuitively, sharing is more likely among commonly generated receptors (i.e., with 
a high 𝑃post(σ)) and within cohorts with larger sampling (Methods). Importantly, rare receptors (i.e., 
with a low 𝑃post(σ)) that are shared among individuals in a common disease group can signal 
commonality in function and a response to a common antigen, as previously observed for TCRs in 
response to a yellow fever vaccine (Pogorelyy et al., 2018b), CMV and diabetes (Pogorelyy et al., 
2018a). We used the receptors’ probabilities 𝑃post(σ)  to assess the significance of sharing by 
identifying a probabilistic threshold to limit the shared outliers both among the COVID-19 patients 
(dashed line in Fig. 5) and the healthy individuals (dashed line in Fig. S7). Out of a total of 33,660 
(unique) progenitors of clonal lineages (Fig. 5A), we found 5,112 progenitors to be shared among at 
least two individuals; 152 of the 5,112 were classified as rare, having a probability of occurrence below 
the indicated threshold (dashed line) in Fig. 5B. Moreover, we found that 439 lineages shared a 
common sequence ancestor in at least two individuals and have expanded in at least one of the 
individuals (Fig. 5C-D). 34 of these shared, expanding lineages stemmed from rare naïve progenitors 
(below the dashed line in Fig. 5B, D). The sharing of these rare expanding BCRs among COVID-19 
patients indicates a potentially convergent response to SARS-CoV-2 (Table S3).  
 
Interestingly, we found that 20% of receptors in these rare shared, expanding lineages contain multiple 
cysteines in their HCDR3s, in contrast to only 10% of the receptors in the whole repertoire. Such 
sequence patterns with cysteine pairs in the HCDR3 have been associated with stabilization of the 
HCDR3 loop by forming disulfide bonds with particular patterns and spacings of the cysteines (Lee 
et al., 2014; Prabakaran and Chowdhury, 2020). Disulfide bonds in the HCDR3 can decrease the 
conformational flexibility of the loop, thus decreasing the entropic cost of binding to improve the 
affinity of the receptor (Almagro et al., 2012). The significantly larger fraction of multi-cysteine 
HCDR3s among the candidate SARS-CoV-2 responsive receptors (p-value = 10-9 based on binomial 
sampling) indicates an underlying molecular mechanism for developing a potent response to SARS-
CoV-2. 
 
Presence of SARS-CoV-2 and SARS-specific neutralizing antibodies within repertoires. Previous 
studies have identified a number of antibodies responsive to the RBD of SARS-CoV-2 (Cao et al., 
2020; Pinto et al., 2020; Robbiani et al., 2020). In repertoires of the COVID-19 patients, we found that 
several HCDR3s matched with SARS-CoV-2-specific monoclonal antibodies (mAbs) that were 
previously isolated in other studies (Table S3). Specifically, three distinct SARS-CoV-2-specific 
mAbs were found to be close in sequence to HCDR3s in our data, with only one amino acid difference, 
and one of these mAbs also had a matching V gene (Table 1). Among these, we found a class of 
antibodies containing multiple cysteines in their HCDR3s, with the potential to form disulfide bonds 
to enhance their affinity to antigens and paratope diversity (Almagro et al., 2012; Lee et al., 2014; 
Prabakaran and Chowdhury, 2020). 
 
In addition, we found that two patients had exact HCDR3 matches to a previously identified antibody 
(S304) that has cross-reactivity to SARS-CoV and SARS-CoV-2 (Pinto et al., 2020). We also observed 
in one patient a HCDR3 with only one amino acid difference to this antibody (Table 1). Importantly, 
the plasma in these patients showed a substantial binding level (OD450) to SARS-CoV (Fig. S3), which 
indicates a possibility of cross-reactive antibody responses to SARS-CoV and SARS-CoV-2.  
 
It should be noted that all of the previously verified antibodies that we identify in the patients’ 
repertoires have a relatively high probability 𝑃post(σ)  of generation and entry to the periphery 
(indicated by yellow diamonds in Fig. 5B). This is not surprising as it is very unlikely to observe rare 
BCRs (with small 𝑃post(σ)) to be shared in multiple individuals. Overall, our results are encouraging 
for vaccine development since they indicate that even common antibodies can confer specific 
responses against SARS-CoV-2. 
 
Discussion 
 
A repertoire of immune receptor sequences presents a unique snapshot of the history of immune 
responses in an individual (Boyd et al., 2009; Georgiou et al., 2014; Kreer et al., 2020; Robins, 2013), 
and the changes in a repertoire during an infection can signal specific responses to pathogens (Horns 
et al., 2019; Nourmohammad et al., 2019). Identifying signatures of a functional response to a given 
pathogen from the pool of mostly unspecific BCRs collected from the blood is challenging—it is a 
problem of finding a needle in a haystack. Therefore, principled statistical inference approaches are 
necessary to extract functional signal from such data. Here, we characterized the B-cell repertoire 
response to SARS-CoV-2 in COVID-19 patients with different disease severity by combining 
evidence from the overall statistics of repertoires together with dynamics of clonal lineages during 
infection and the sharing of immune receptors among patients. 
 
At the repertoire level, we showed that HCDR3 of BCRs in COVID-19 patients are significantly longer 
than HDCR3 in healthy individuals, and the amino acid composition of this receptor region varies 
among cohorts of patients with mild, moderate, and severe symptoms. Moreover, we observed large-
scale sharing of B-cell receptors among COVID-19 patients, consistent with previous findings in 
COVID-19 patients (Galson et al., 2020; Nielsen et al., 2020; Schultheiß et al., 2020). Sharing of 
receptors among individuals can signal common immune responses to a pathogen. However, BCR 
sharing can also be due to convergent recombination leading to the same receptor sequence or other 
experimental biases that influence statistics of shared sequences. These statistical nuances can 
substantially sway conclusions drawn from the sharing analysis and, therefore, should be carefully 
accounted for. Here, we established a null expectation of BCR sharing due to convergent 
recombination by inferring a model of receptor generation and migration to the periphery and used 
this null model to identify sequence outliers. Our analysis identified a subset of rare BCRs shared 
among COVID-19 patients, which appears to signal convergent responses to SARS-CoV-2. 
 
In addition to the statistics of repertoires, we observed that the activity of many B-cell lineages (i.e., 
mRNA production) in COVID-19 patients significantly increases during infection, accompanied by 
an increase in the binding level (OD450) of the patients’ sera to the RBD and NTD of SARS-CoV-2. 
Dynamics of clonal lineages during an infection provide significant insights into the characteristics of 
responsive antibodies (Horns et al., 2019; Nourmohammad et al., 2019). By taking advantage of data 
collected at multiple time points in most patients, we identified expanded lineages shared among 
patients and found 34 clonal lineages that are candidates for a specific response specific to SARS-
CoV-2 antigens. Further analysis would be required to determine the reactivity of these antibodies 
against the RBD or NTD of SARS-CoV-2.  
 
Identifying antibodies with cross-reactive neutralization abilities against viruses in the SARS family 
is of significant interest. Interestingly, in nine patients, we see a substantial increase in the binding 
level (OD450) of their sera to SARS-CoV epitopes during the course of COVID-19 infection. 
Moreover, in three patients, we identify a BCR identical to the heavy chain of antibody S304 (Pinto 
et al., 2020), which was previously isolated from a patient who recovered from a SARS-CoV infection. 
This antibody was shown to be moderately cross-reactive to both SARS-CoV and SARS-CoV-2, and 
our results further indicate a possibility for such cross-reactive antibodies to emerge naturally in 
response to SARS-CoV-2 (Brouwer et al., 2020; Lv et al., 2020; Rogers et al., 2020). Taken together, 
our findings provide substantial insight and strong implications for devising vaccines and therapies 
with a broad applicability against SARS-CoV-2. 
  
Materials and Methods 
 
Experimental procedures 
 
Sample collection and PBMC isolation. Specimens of heparinized blood were collected from the 
RT-PCR-confirmed COVID-19 patients at the Infectious Disease Centre of the Princess Margaret 
Hospital, Hong Kong. The study was approved by the institutional review board of the Hong Kong 
West Cluster of the Hospital Authority of Hong Kong (approval number: UW20-169). All study 
procedures were performed after informed consent was obtained. Day 1 of clinical onset was defined 
as the first day of the appearance of clinical symptoms. The severity of the COVID-19 cases was 
classified based on the adaptation of the Sixth Revised Trial Version of the Novel Coronavirus 
Pneumonia Diagnosis and Treatment Guidance. The severity of the patients was categorized as 
follows: Mild - no sign of pneumonia on imaging, mild clinical symptoms; Moderate - fever, 
respiratory symptoms and radiological evidence of pneumonia; Severe - dyspnea, respiratory 
frequency >30/min, blood oxygen saturation 93%, partial pressure of arterial oxygen to fraction of 
inspired oxygen ratio <300, and/or lung infiltrates >50% within 24 to 48 hours; Critical - respiratory 
failure, septic shock, and/or multiple organ dysfunction or failure or death. 
 
The blood samples were first centrifuged at 3000 xg for 10 minutes at room temperature for plasma 
collection. The remaining blood was diluted with equal volume of PBS buffer, transferred onto the 
Ficoll-Paque Plus medium (GE Healthcare), and centrifuged at 400 xg for 20 minutes. Peripheral 
Blood Mononuclear Cells (PBMC) samples were then collected and washed with cold RPMI-1640 
medium for three times. The isolated PBMC samples were finally stored at cell freezing solution (10% 
DMSO + 90% FBS) and kept in -80oC until used. 
 
RNA extraction and reverse transcription. Total RNA was extracted from 5 × 109 PBMC using 
the RNeasy Mini isolation kit (Qiagen) according to the manufacturer’s protocol. Reverse transcription 
of the RNA samples was performed using the Proto- Script® II Reverse Transcriptase kit (New 
England Biolabs, NEB) with random hexamer primers according to the manufacturer’s protocol. The 
thermal cycling conditions were designed as follows: 25oC for 5 minutes, 42oC for 60 minutes, and 
80oC for 5 minutes. The resulting cDNA samples were stored in 80oC freezer before PCR was 
performed. 
 
Amplification of B cell repertoire from the samples by PCR. The cDNA samples were used as a 
template to amplify the antibody IgG heavy chain gene with six FR1-specific forward primers and one 
constant region-specific reversed primer using the Phusion® High-Fidelity DNA Polymerase. The 
primer sequences were the same as previously described (Wu et al., 2015); primer sequences are listed 
in Table S2. The thermal cycling conditions were set as follows: 98oC for 30 seconds; 30 cycles of 
98oC for 10 seconds, 58oC for 15 seconds, and 72oC for 30 seconds; and 72oC for 10 minutes. Then 
10 ng of the PCR product was used as a template for the next round of gene amplification with sample-
specific barcode primers. The thermal cycling conditions were set as follow: 98oC for 3 min; 30 cycles 
of 98oC for 10 seconds, 58oC for 15 seconds, and 72oC for 15 seconds; and a final extension at 72oC 
for 10 min using Phusion® High-Fidelity DNA Polymerase. The PCR product was purified by 
QIAquick Gel Extraction Kit (Qiagen), and quantified by NanoDrop Spectrophotometers 
(Thermofisher). 
 
Cell lines. Sf9 cells (Spodoptera frugiperda ovarian cells, female, ATCC catalogue no. CRL-1711) 
and High Five cells (Trichoplusia ni ovarian cells, female; Thermo Fisher Scientific, Waltham, United 
States (US), catalogue number: B85502) were maintained in HyClone (GE Health Care, Chicago, US) 
insect cell culture medium. 
 
Protein expression and purification. The receptor-binding domain (RBD, residues 319–541) and N-
terminal domain (NTD, residues 14 to 305) of the SARS-CoV-2 spike protein (GenBank: 
QHD43416.1) as well as the RBD (residues 306-527) and NTD (residues 14-292) of SARS-CoV spike 
protein (GenBank: ABF65836.1) were cloned into a customized pFastBac vector (Lv et al., 2020; Wec 
et al., 2020). The RBD and NTD constructs were fused with an N-terminal gp67 signal peptide and a 
C-terminal His6 tag. Recombinant bacmid DNA was generated using the Bac-to-Bac system (Life 
Technologies, Thermo Fisher Scientific). Baculovirus was generated by transfecting purified bacmid 
DNA into Sf9 cells using FuGENE HD (Promega, Madison, US) and subsequently used to infect 
suspension cultures of High Five cells (Life Technologies) at a multiplicity of infection (moi) of 5 to 
10. Infected High Five cells were incubated at 28 °C with shaking at 110 rpm for 72 h for protein 
expression. The supernatant was then concentrated using a Centramate cassette (10 kDa molecular 
weight cutoff for RBD, Pall Corporation, New York, USA). RBD and NTD proteins were purified by 
Ni-NTA Superflow (Qiagen, Hilden, Germany), followed by size exclusion chromatography and 
buffer exchange to phosphate-buffered saline (PBS). 
 
ELISA. A 96-well enzyme-linked immunosorbent assay (ELISA) plate (Nunc MaxiSorp, Thermo 
Fisher Scientific) was first coated overnight with 100 ng per well of purified recombinant protein in 
PBS buffer. The plates were then blocked with 100 µl of Chonblock blocking/sample dilution ELISA 
buffer (Chondrex Inc, Redmon, US) and incubated at room temperature for 1 h. Each human plasma 
sample was diluted to 1:100 in Chonblock blocking/sample dilution ELISA buffer. Each sample was 
then added into the ELISA plates for a two-hour incubation at 37°C. After extensive washing with 
PBS containing 0.1% Tween 20, each well in the plate was further incubated with the anti-human IgG 
secondary antibody (1:5000, Thermo Fisher Scientific) for 1 hour at 37°C. The ELISA plates were 
then washed five times with PBS containing 0.1% Tween 20. Subsequently, 100 µL of HRP substrate 
(Ncm TMB One; New Cell and Molecular Biotech Co. Ltd, Suzhou, China) was added into each well. 
After 15 min of incubation, the reaction was stopped by adding 50 µL of 2 M H2SO4 solution and 
analyzed on a Sunrise (Tecan, Männedorf, Switzerland) absorbance microplate reader at 450 nm 
wavelength. 
 
BCR processing and computational procedures 
 
BCR preprocessing. For initial processing of the raw reads, we used pRESTO (version 0.5.13) 
(Vander Heiden et al., 2014) to assemble paired-end reads, remove sequences with a mean quality 
score less than 30, mask primer subsequences, and collapse duplicate sequences into unique 
sequences. The small fraction of paired-end reads that overlapped were assumed to be anomalous and 
were discarded from the analysis. Additionally, after preprocessing with pRESTO, we discarded 
unique reads that contained ambiguous calls (N’s) in their receptor sequence. 
 
BCR error correction. We performed two rounds of error correction on sequences that passed the 
quality control check. In the first round, we clustered singletons and other low-frequency sequences 
into larger sequences if they were similar in sequence. The intent of this round was to correct for 
sequencing errors (e.g. from reverse transcription of mRNA to cDNA) that caused large abundance 
clones to be split into many similar sequences. We used two parameters: Δ; = 1.0, the marginal 
Hamming distance tolerance per decade in log-ratio abundance (each log10 unit allowing Δ; 
additional sequence differences), and Δ> = 1.0 , the marginal abundance tolerance of clusterable 
sequences per decade in log-ratio abundance (each log10 unit allowing abundance Δ>  higher as 
clusterable). For example, a sequence with abundance 𝑎3 and a Hamming distance 𝑑 away from a 
higher abundance sequence with abundance 𝑎A was absorbed into the latter only if 𝑑 ≤ Δ; 	log34 >C>D 
and 𝑎3 ≤ Δ> log34 >C>D. We used the output of this first round as input for the second round of error 
correction, in which we more aggressively target correction of reverse transcriptase errors. In the 
second round, we used two different parameters to assess sequence similarity: 𝑑thresh = 2.0, the 
Hamming distance between sequences, and 𝑎thresh = 1.0 , the ratio of sequence abundances. A 
sequence with abundance 𝑎3 and a Hamming distance 𝑑 away from a sequence of larger abundance 𝑎A was absorbed into the latter only if 𝑑 ≤ 𝑑thresh and the ratio of the sequence abundances was 
greater than 𝑎thresh, i.e. >C>D ≥ 𝑎thresh. This round of error correction allows much larger abundance 
sequences to potentially be clustered than is possible in the first round. For both of the above steps, 
we performed clustering greedily and approximately by operating on sequences sorted by descending 
abundance, assigning the counts of the lower abundance sequence to the higher abundance one 
iteratively. 
 
After error correction, the sequences still contained a large number of singletons, i.e. sequences with 
no duplicates (Table S1). We discarded these singletons from all analyses that relied on statistics of 
unique sequences (i.e., the results presented in Figs. S1, S2C,E,F). 
 
BCR annotation. For each individual, error-corrected sequences from all timepoints and replicates 
were pooled and annotated by abstar (version 0.3.5) (Briney and Burton, 2018). We processed the 
output of abstar, which included the estimated V gene/allele, J gene/allele, location of the HCDR3 
region, and an inferred naïve sequence (germline before hypermutation). Sequences which had indels 
outside of the HCDR3 were discarded. We partitioned the sequences into two sets: productive BCRs, 
which were in-frame and had no stop codons, and unproductive BCRs, which were out-of-frame. 
 
Unproductive BCRs. Due to a larger sequencing depth in healthy individuals, we were able to 
reconstruct relatively large unproductive BCR lineages. Unproductive sequences are BCRs that are 
generated but, due to a frameshift or insertion of stop codons, are never expressed. These BCRs reside 
with productive (functional) BCRs in a nucleus and undergo hypermutation during B-cell replication 
and, therefore, provide a suitable null expectation for generation of BCRs in immune repertoires. 
 
Clonal lineage reconstruction. To identify BCR clonal lineages, we first grouped sequences by their 
assigned V gene, J gene, and HCDR3 length and then used single-linkage clustering with a threshold 
of 85% Hamming distance. A similar threshold has been suggested previously by (Gupta et al., 2017) 
to identify BCR lineages. Clusters of size smaller than three were discarded from our analysis, size 
being defined as the sum of the amount of unique sequences per time point within a lineage. For each 
cluster, there may have been multiple inferred naïve sequences, as this was an uncertain estimate. 
Therefore, the most common naïve sequence was chosen to be the naïve progenitor of the lineage. 
When the most common naïve sequence of a productive lineage contained a stop codon, the progenitor 
of the lineage was chosen iteratively by examining the next most common naïve sequence until it did 
not contain any stop codons. If all inferred naïve sequences in a productive lineage had a stop codon, 
that lineage was discarded from the analysis. Table S1 shows the statistics of constructed clonal 
lineages in each individual. 
 
Inference of generation probability and selection for BCRs. We used IGoR (version 1.4) (Marcou 
et al., 2018) to obtain a model of receptor generation. This model characterized the probability of 
generation 𝑃gen(σ) of a receptor dependent on the features of the receptor, including the V, D, and J 
genes and the deletion and insertion profiles at the VD and DJ junctions. To characterize the 
parameters of this model, we trained IGoR on the progenitors of all unproductive lineages, regardless 
of size, pooled from all cohorts. For consistency with our receptor annotations based on abstar, we 
used abstar’s genomic templates and the HCDR3 anchors of abstar’s reference genome as inputs for 
IGoR’s genomic templates and HCDR3 anchors. 
 
We used SONIA (version 0.27) (Sethna et al., 2020) to infer a selection model for progenitors of 
productive clonal lineages. The SONIA model evaluated selection factors 𝑞  to characterize the 
deviation in the probability 𝑃post(σ) to observe a functional sequence in the periphery from the null 
expectation, based on the generation probability 𝑃gen(σ): 𝑃post(σ) = 3G 𝑃gen(σ)𝑒'(:features*((+), where 𝑍 
is the normalization factor and 𝑞.(σ) are selection factors dependent on the sequence features 𝑓. 
These sequence features include V-gene and J-gene usages and HCDR3 length and amino acid 
composition (Sethna et al., 2020).  
 
In our analysis, we used the SONIA left-right model with independent V- and J-gene usages (Sethna 
et al., 2020). We used the output from IGoR as the receptor generation model for SONIA. We trained 
four cohort-specific SONIA models on progenitors of all productive lineages, regardless of size, 
pooled from all individuals within a cohort. 150 epochs and 500,000 generated sequences were used 
to train each SONIA model. Fig. 3 shows the distributions for the probabilities of observing productive 
receptors sampled from each cohort 𝑃post(σ) and the correlation of feature-specific selection factors 𝑞. among cohorts. 
 
Characterizing repertoire diversity. We quantified the diversity of each cohort by evaluating the 
entropy of receptor sequences in each cohort. Estimates of entropy can be influenced by how each 
distribution is sampled. To avoid such sampling biases, we used the inferred IGoR and SONIA models 
to generate 500,000 synthetics receptors based on each of the cohort-specific models. We evaluated 
cohort entropies 𝐻  as the expected log-probabilities to observe a functional sequence in the 
respective cohort: 𝐻 = −∑ 𝑃post(σ) log 𝑃post (σ)+ . 
 
For comparison, we also evaluated the entropy estimated on the repertoire data in each cohort, which 
showed a similar pattern to the estimates from the generated cohorts (in the main text). Specifically, 
the entropy of BCR repertoires estimated from the data follows: 39.8 ± 0.3  bits in healthy 
individuals, 41.9 ± 0.7  bits for patients in the mild cohort, 42.6 ± 0.3  bits for patients in the 
moderate cohort, and 42.8 ± 0.5 for patients in the severe cohort. The error bars indicate the standard 
error due to differences among individuals within a cohort. 
 
Clonal Lineage expansion. We studied clonal lineage expansion of BCR repertoires in individuals 
that showed an increase in the binding level (OD450) of their plasma to SARS-CoV-2 (RBD) during 
infection (Figs. 4A, S3): patients 2, 3, 4, 5, 6, 7, 9, 10, 11, 13, 14. Other individuals showed no increase 
in IgG binding to SARS-CoV-2 (RBD), either due to already high levels of binding at early time points 
or to natural variation and noise (Fig. S3). Our expansion test compared two time points. Therefore, 
for individuals with three time points, we combined data from different time points such that the 
separated times coincided with larger changes in binding levels (OD450). Specifically, we combined 
the last two time points for patients 2 and 7 and the first two time points for patient 9. In addition, we 
combined replicates at the same time point and filtered out small lineages with size < 3, where size 
was defined as the sum of the amount of unique sequences per time-point within a lineage. 
 
To test for expansion, we compared lineage abundances (i.e., total number of reads in a lineage) 
between early and late time points. Many lineages appeared only in one time point due to the sparse 
sampling of clonal lineages and the cells that generate them (Fig. S4). Therefore, we tested for 
expansion only for lineages that had nonzero abundances at both time points. 
 
Our expansion test relied on comparing the relative abundance of a given lineage with other lineages. 
However, due to primer-specific amplification biases, abundances were not comparable between reads 
amplified with different primers. Therefore, in our analysis we only compare a lineage with all other 
lineages that were amplified with the same primer. 
 
We applied a hypergeometric test (Fisher’s exact test) to characterize significance of abundance fold 
change for a focal lineage. A similar method was used to study clonal expansion in TCRs (DeWitt et 
al., 2015). For each focal clonal lineage 𝑖 (in a given individual), we defined a 2	 × 2 contingency 
matrix 𝐶, 
C = W𝑛Yearly 𝑁/Yearly𝑛Ylate 𝑁/Ylate \	
 
where 𝑛Yearly and 𝑛Ylate are the abundances of the focal lineage at the early and late time, and 𝑁/Yearly 
and 𝑁/Ylate are the total abundances of all reads (with the same primer) minus those from lineage 𝑖 at 
the early and late times. The ratio (𝑛Ylate/𝑛Yearly)/(𝑁/Y]^_`	/𝑁/Y`^ a]b	) describes the fold change, or odds 
ratio, of lineage 𝑖 relative to the rest of the reads in the same primer group. Based on the contingency 
matrix 𝐶, one-sided p-values for Fisher’s exact test were calculated using the “fisher.test” function in 
R version 4.0. Fold change and p-values are shown in Fig. S6A. 
 
To determine a significance threshold for the Fisher’s exact test, we examined the replicate data from 
samples collected from the same time point in each individual because we did not expect any 
significant expansion among replicates. We calculated the expansion test on pairs of replicates (Fig. 
S5B,C), and we compared the empirical cumulative distributions of the time point and replicate 
expansion data (Fig. S5D,E) (Storey, 2002; Storey and Tibshirani, 2003). We chose a p-value 
threshold of 10cd44, where there were 12.3 as many significant expansions as in the replicate data, 
and therefore the false discovery rate was approximately 1/(1 + 12.3) = 0.075. 
 
Significance of BCR sharing among individuals. The probability that receptor σ is shared among 
a given number of individuals due to convergent recombination can be evaluated based on the 
probability to observe the receptor in the periphery 𝑃post(σ), the size of the cohort 𝑀, and the size of 
the repertoire (sequence sample size) 𝑁. First, we evaluated the probability ρ(σ;𝑁) that receptor σ 
with probability 𝑃post(σ) appears at least once in a sample of size 𝑁,  ρ(σ;𝑁) = 1 − j1 − 𝑃post(σ)kl ≃ 1 − 𝑒clnpost  
The probability that receptor σ	is shared among 𝑚 individuals out of a cohort of 𝑀 individuals, 
each with a (comparable) sample size 𝑁, follows the binomial distribution, 
 𝑃share(σ;𝑚,𝑀, 𝑁) = u𝑀𝑚v [ρ(σ;𝑁)]y[1 − ρ(σ;𝑁)]zcy 
 
We aimed to identify shared receptors that were outliers such that their probability of sharing is too 
small to be explained by convergent recombination or other biases in the data. To do so, we identified 
the receptors with the smallest sharing probabilities 𝑃share and found a threshold of 𝑃post (dashed 
lines in Fig. 5 and Fig. S7) at the 1% quantile of 𝑃share in the data. Specifically, since 𝑃share is a 
function of 𝑃post and 𝑚 (number of individuals sharing), for each 𝑚 we solved for 𝑃post such that 𝑃share 	= 	𝑐, and tuned the constant	𝑐  such that only 1% of the data lay below 𝑃share. This was a 
conservative choice to identify the rare shared outliers in the data. 
 
Accessibility and resources.  
BCR repertoire data can be accessed through: 
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA645245 
  
All codes for data processing and statistical analysis can be found at: 
https://github.com/StatPhysBio/covid-BCR 
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Figure 1. Roadmap for analysis of BCR repertoires. Top: We collected bulk blood IgG BCR samples from three healthy 
individuals and 19 COVID-19 patients where two patients had mild symptoms, 12 had moderate symptoms, and five had 
severe symptoms (different markers and colors) (See Methods). Samples were collected at different time points during 
infection (shown in center). We distinguished between productive receptors and unproductive receptors that had 
frameshifts due to V(D)J recombination. In each patient, we constructed clonal lineages for productive and unproductive 
BCRs and inferred the naïve progenitor of the lineage (Methods). Bottom: 1. We inferred a model (Marcou et al., 2018) 
to characterize a null probability for generation of receptors 𝑃gen(𝜎), trained on the set of unproductive inferred naïve 
BCRs. We inferred a selection model (Isacchini et al., 2020b) to characterize the deviation from the null among inferred 
naïve productive BCRs using the probability of entry to the periphery 𝑃post(𝜎) and characterize selection factors 𝑞.(𝜎) 
dependent on sequence features to differentiate between cohort statistics. 2. Based on temporal information of sampled 
BCRs, we identified clonal lineages that showed significant expansion during infection. 3. We identified progenitors of 
clonal lineages shared among individuals and assess the significance of these sharing statistics based on the probabilities 
to find each receptor in the periphery. We also identified previously characterized monoclonal antibodies (mAbs) specific 
to SARS-CoV-2 and SARS-CoV. 
 
 
 
 
 
 
 
 
Figure 2. Sequence features of immune receptors across cohorts. (A) The normalized probability density function 
(PDF) for IGHV-gene usage is shown for inferred naïve progenitors of clonal lineages in cohorts of healthy individuals 
and COVID-19 cohorts of patients exhibiting mild, moderate, and severe symptoms. The bars indicate the usage frequency 
averaged over individuals in each cohort, and dots indicate the variation in V-gene frequencies across individuals within 
each cohort. (B) Distribution of length of HCDR3 amino acid sequence, (C) length of nucleotide sequence insertions at 
the VD junction, and (D) length of nucleotide sequence deletions at the VD junction are shown for each cohort. Full lines 
show distributions averaged over individuals in each cohort, and shadings indicate regions containing one standard 
deviation of variation among individuals within a cohort. The inferred naïve progenitors of clonal lineages in healthy 
individuals show significantly shorter HCDR3s, shorter VD deletions, and longer VD insertions compared to COVID-19 
patients with moderate and sever symptoms. ANOVA statistics for mean HCDR3 length between cohorts: Healthy-Mild: 𝐹3,d = 12.0, p-value = 0.040; Healthy-Moderate: 𝐹3,3d = 15.7, p-value = 0.002; Healthy-Severe: 𝐹3,} = 37.3, p-value = 
0.001. ANOVA statistics for mean VD deletion length between cohorts: Healthy-Mild: 𝐹3,d = 4.2, p-value = 0.133; 
Healthy-Moderate: 𝐹3,3d = 12.6, p-value = 0.004; Healthy-Severe: 𝐹3,} = 19.1, p-value = 0.005. ANOVA statistics for 
mean VD insertion length between cohorts: Healthy-Mild: 𝐹3,d = 3.7, p-value = 0.152; Healthy-Moderate: 𝐹3,3d = 10.0, 
p-value = 0.008; Healthy-Severe: 𝐹3,} = 8.2, p-value = 0.03. 
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Figure 3. Differential statistics of immune repertoires across cohorts. (A) The distribution of the log-probability to 
observe a sequence 𝜎 in the periphery log34 𝑃post (𝜎) is shown for inferred naïve progenitors of clonal lineages in cohorts 
of healthy individuals and the mild, moderate, and severe cohorts of COVID-19 patients. Full lines show distributions 
averaged over individuals in each cohort, and shadings indicate regions containing one standard deviation of variation 
among individuals within a cohort. (B) Correlation between the inferred feature-specific selection factors 𝑞. for V-gene 
usage (left), HCDR3 length preference (middle), and HCDR3 amino acid usage (right) is shown among cohorts. 
Correlation values associated with each color is indicated in the matrices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Dynamics of BCR repertoires during infection. (A) The binding level (measured by OD450 in ELISA assay) 
of the IgM (left) and IgG (right) repertoires to SARS-CoV-2 (RBD) epitopes increases over time in most individuals. (B) 
The log-ratio of BCR (mRNA) abundance at late time versus early time is shown for all clonal lineages that are present at 
least in two time points (see Methods). Each panel shows dynamics of lineages for a given individual, as indicated in the 
label. The analysis is shown in individuals for whom the binding level (OD450) of the IgG repertoire increases over time 
(shown in (A)). The count density indicates the number of lineages at each point. Lineages that show a significant 
expansion over time are indicated in red (see Methods for estimation of associated p-values). (C) IGHV-gene usage of 
lineages is shown for non-expanded (left) and expanded (middle) lineages in all individuals (colors). The right panel shows, 
for each patient (colors), the fraction of expanded lineages with a given IGHV gene as the number of expanded lineages 
divided by the total number of lineages with that given IGHV gene. The size of the circles indicates the total number of 
lineages in each category. 
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Figure 5. Sharing of BCRs among patients. (A) The histogram shows the number of clonal lineages that share a common 
progenitor in a given number of individuals, indicated on the horizontal axis. (B) The density plot shows the distribution 
of 𝑃post  for progenitors of clonal lineages shared in a given number of individuals, indicated on the horizontal axis; 
Histogram bin size is 0.5. The scaling of sequence counts sets the maximum of density in each column to one. Sharing of 
rare lineages with 𝑃post 	below the dashed line is statistically significant (see Methods). Red diamonds indicate clonal 
lineages below the dashed line with significant expansion in at least one of the individuals, identified in Fig. 4. Yellow 
triangles indicate HCDR3 matches with previously identified SARS-CoV-2 specific mAbs. (C) The histogram shows the 
number of clonal lineages that share a common progenitor in a given number individuals, indicated on the horizontal axis, 
and which have significantly expanded (Fig. 4) during infection in at least one of the individuals. (D) The scatter plot with 
transparent overlapping markers shows 𝑃post	for progenitors of clonal lineages shared in a given number individuals that 
have expanded in at least one individual, shown in (C). The dashed line indicates 𝑃post-dependent significance of sharing, 
similar to (B). 
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 verified antibody observed antibody 
ID IGHV HCDR3 target IGHV HCDR3 Patient ID 
BD-494 (Cao et al., 2020) 
BD-498 (Cao et al., 2020) 
BD-507 (Cao et al., 2020) 
IGHV3-53 
IGHV3-66 
IGHV3-53 
ARDLVVYGMDV SARS-2: RBD 
IGHV4-59 
IGHV4-39 
IGHV4-61 
IGHV4-34 
ARDLVVGGMDV 7 
COV21.2 (Robbiani et al., 2020) 
COV57.2 (Robbiani et al., 2020) 
COV107.2 (Robbiani et al., 
2020) 
IGHV1-58 
AAPHCSGGSCYDAFDI 
AAPYCSGGSCNDAFDI 
AAPYCSGGSCSDAFDI 
SARS-2: RBD IGHV1-58 
AAPYCSGGSCYDAFDI 
AAPYCSGGSCYDAFDI 
AAPYCSGGSCFDAFDI 
6 
6 
9 
B38 (Wu et al., 2020b) IGHV3-53 AREAYGMDV SARS-2: RBD IGHV3-66 ARGAYGMDV 
13 
14 
15 
S304 (Pinto et al., 2020) IGHV3-13 AKGDSSGYYYYFDY SARS IGHV3-13 
AKGDSSGYYYYFDY 
AKGDSSGYYYYFDY 
ARGYSSGYYYYFDY 
5 
7 
13 
 
Table 1. Verified antibodies detected in BCR repertoires of COVID-19 patients. Verified antibodies responsive to 
SARS-CoV-2 or SARS-CoV, whose HCDR3 sequences match with a receptor (with up to Hamming distance of one amino 
acid) in the BCR repertoires of patients in this study are shown. Mutations with respect to the original HCDR3 are in red. 
Single amino acid mutations among HCDR3 of verified antibodies are in cyan. The complete list of verified antibodies is 
given in Table S3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Features of unique immune receptors across cohorts. (A) IGHV-gene usage is shown for unique receptors 
in cohorts of healthy individuals and COVID-19 cohorts of patients exhibiting mild, moderate, and severe symptoms. The 
bars indicate the usage frequency averaged over individuals in each cohort, and dots indicate the variation in V-gene 
frequencies across individuals within each cohort. (B) Distribution of the length of HCDR3 amino acid sequence, (C) the 
length of nucleotide sequence insertion at the VD junction, and (D) the length of nucleotide sequence deletion at the VD 
junction are shown for each cohort. Full lines show distributions averaged over individuals in each cohort, and shading 
indicates regions containing one standard deviation of variation among individuals within a cohort. Unique BCRs in 
healthy individuals show significantly shorter HCDR3s compared to moderate and sever cohorts, and significantly shorter 
VD deletions, and longer VD insertions compared to only the moderate cohort. ANOVA statistics for mean HCDR3 length 
between cohorts: Healthy-Mild: 𝐹3,d = 8.7, p-value = 0.060; Healthy-Moderate: 𝐹3,3d = 17.2, p-value = 0.001; Healthy-
Severe: 𝐹3,} = 10.0, p-value = 0.020. ANOVA statistics for mean VD deletion length between cohorts: Healthy-Mild: 𝐹3,d = 1.7, p-value = 0.288; Healthy-Moderate: 𝐹3,3d = 9.5, p-value = 0.009; Healthy-Severe: 𝐹3,} = 4.5, p-value = 0.08. 
ANOVA statistics for mean VD insertion length between cohorts: Healthy-Mild: 𝐹3,d = 2.1, p-value = 0.241; Healthy-
Moderate: 𝐹3,3d = 10.1, p-value = 0.007; Healthy-Severe: 𝐹3,} = 4.3, p-value = 0.08. 
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Figure S2. IGHJ-gene usage and insertion/deletion at DJ junctions. IGHJ-gene usage is shown for lineage progenitors 
(A) and for unique receptors (B) in cohorts of healthy individuals and COVID-19 cohorts of patients exhibiting mild, 
moderate, and severe symptoms. The bars indicate the usage frequency averaged over individuals in each cohort, and dots 
indicate the variation in J-gene frequencies across individuals within each cohort. Distributions of the length of nucleotide 
sequence insertion (C) and deletion (D) at the DJ junction are shown for lineage progenitors. (E) and (F) show similar 
statistics to (C) and (D) for unique receptors in each cohort. (C-F) Full lines show distributions averaged over individuals 
in each cohort, and shadings indicates regions containing one standard deviation of variation among individuals within a 
cohort. The inferred naïve progenitors of clonal lineages in healthy individuals show significantly longer DJ insertions, 
and shorter DJ deletions compared to COVID-19 patients with moderate symptoms. ANOVA statistics for mean DJ 
insertion length between Healthy-Moderate: 𝐹3,3d = 12.4, p-value = 0.004, and for mean DJ deletion length between 
Healthy-Moderate: 𝐹3,3d = 10.9, p-value = 0.006. The differences in the statistics of DJ indels between healthy individuals 
and other infected cohorts are insignificant (ANOVA p-value > 0.01). The differences in statistics of DJ indels for unique 
BCRs are insignificant between cohorts.   
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 Figure S3. ELISA binding assays for IgG and IgM repertoires against SARS-CoV-2 and SARS-CoV. Plasma binding 
levels (measured by OD450 in ELISA) against RBD, NTD, and S2 epitopes of SARS-CoV-2 and against RBD and NTD 
epitopes of SARS-CoV are shown. As seen in binding assays, many individuals developed a cross-reactive response to 
SARS-CoV-2 and SARS-CoV. Some individuals showed no increase in IgG binding to SARS-CoV-2 RBD due to already 
high levels at sampling time or natural variation. For the expansion analysis (Fig. 4), we analyzed only individuals whose 
IgG repertoires showed an increase in binding to SARS-CoV-2 (RBD): 2, 3, 4, 5, 6, 7, 9, 10, 11, 13, and 14. 
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Figure S4. Overlap of BCR lineages between samples from each individual. BCR repertoires are highly under-
sampled, and relatively few BCR lineages appear in multiple time points and replicates. (A) Fraction of lineages 
present in only one time point before (blue) and after (red) filtering out small lineages (i.e., those with less than three 
unique sequences per time point) are shown. (B) Fraction of lineages present in only one replicate before (blue) and 
after (red) filtering out small lineages (i.e., those with less than three unique sequences per time point) are shown.  
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Figure S5. Expansion test with replicate data. (A) The log-ratio of abundance of receptors for all clonal lineages 
present in two replicates are shown. Each panel shows the test result for a given patient, as indicated in the label. 
The count density indicates the number of lineages at each point. Lineages that show a significant expansion over 
time are indicated in red. Since this is replicate data and represents a null model, red points indicate false positives. 
(B) log10 p-values of the expansion test versus log10 fold change (or odds ratio) for replicate data are shown. Color 
indicates density of points, and p-values of zero are displayed at the minimum nonzero value. See Methods for 
normalization, data processing, and hypothesis test. (C) Empirical cumulative distributions of expansion data from 
multiple time points (red) and replicate data (blue) show that many more tests in expansion data result in low p-
values compared to replicate data. (D) Ratio of empirical cumulative distributions indicates that at a significance 
threshold of 10cd44 there are roughly 12.3 times more positives than false positives. 
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Figure S6. Statistics of expansion tests. (A) log10 p-values of the expansion test versus log10 fold change (or odds 
ratio) for data corresponding to Fig. 4B is shown. Color indicates density of points, and p-values of zero are displayed 
at the minimum nonzero value. See Methods for normalization, data processing, and hypothesis test. (B) Fraction of 
lineages expanded for different individuals is shown. HCDR3 length distributions of expanded and non-expanded 
lineages, (C) with each lineage having equal weight, and (D) with each lineage weighted by the number of unique 
sequences per time point (excluding singletons) are shown. 
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Figure S7. Sharing of BCRs among healthy individuals. The density plot shows the distribution of log34 𝑃post 
for progenitors of clonal lineages shared in a given number of healthy individuals, indicated on the horizontal axis; 
Histogram bin size is 0.5. The counts in each bin are scaled such that the maximum is equal to one for each column. 
The numbers above each column indicate the total number of sequences in the respective column. Sharing of rare 
lineages with log34 𝑃post below the dashed line is statistically significant (see Methods). 
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Severity Patient (Sex, Age) Time (replicate) Abundance Singletons Unique sequences Lineages (size > 2) Lineages (size > 10) 
Healthy 
H1 (F, 28) 0 (1) 585886 67557 69985 623 282 
H2 (F, 30) 0 (1) 366626 54765 57112 826 369 
H3 (M, 45) 0 (1) 336339 42613 44106 469 221 
Mild 
1 (F, 62) 
22 (1) 340773 62846 
106373 
2474 1221 
22 (2) 187755 38058 
43 (1) 313753 55415 
101573 
43 (2) 216832 41867 
2 (F, 37) 
2 (1) 234000 44165 44814 
3107 1271 
15 (1) 269510 38632 
90655 15 (2) 136105 24335 
15 (3) 122493 23898 
34 (1) 877806 104879 
209879 34 (2) 299677 48613 
34 (3) 285678 47777 
Moderate 
3 (M, 47) 
8 (1) 513662 73778 
164904 
2718 1251 
8 (2) 127864 27294 
8 (3) 325384 56658 
38 (1) 571769 65093 
132895 38 (2) 141638 24684 
38 (3) 241868 37894 
4 (F, 73) 
18 (1) 317855 37128 
60831 
1222 441 
18 (2) 111427 21487 
34 (1) 235260 39501 
69040 
34 (2) 159067 26999 
5 (F, 72) 
10 (1) 677259 97781 103198 
2696 1216 
27 (1) 829769 105705 110757 
6 (M, 56) 
13 (1) 366489 62644 67365 
2825 1241 
28 (1) 575454 71227 74550 
7 (F, 55) 
11 (1) 559836 85695 91002 
5846 2677 16 (1) 256747 45229 47957 
39 (1) 1385280 183388 192451 
8 (M, 37) 
14 (1) 341447 60690 
101153 
35456 1627 
14 (2) 177401 35116 
32 (1) 394388 58632 
119555 
32 (2) 367276 56757 
37 (1) 330463 48171 
88008 
37 (2) 239495 36775 
9 (F, 52) 
5 (1) 88825 19062 
67036 
3026 1533 
5 (2) 281929 45587 
8 (1) 337280 59940 
114397 
8 (2) 260919 49560 
18 (1) 322636 57263 
118522 
18 (2) 310443 55570 
10 (M, 27) 
8 (1) 56146 7437 
10332 
917 405 
8 (2) 12101 2483 
14 (1) 465583 54671 
81512 
14 (2) 138907 22548 
11 (F, 20) 
10 (1) 526891 75605 
118907 
3010 1421 
10 (2) 177963 36654 
15 (1) 411802 71675 
85572 
15 (2) 25773 8636 
12 (F, 48) 
7 (1) 167253 16442 
20963 
1285 541 
7 (2) 9967 3982 
11 (1) 485491 68900 
130095 
11 (2) 353809 55396 
13 (F, 44) 
7 (1) 502644 44087 
79069 
2868 1491 
7 (2) 269464 31602 
13 (1) 556448 85160 
172192 
13 (2) 436959 75728 
14 (F, 51) 
3 (1) 556305 69852 
137602 
3207 1631 
3 (2) 387828 60574 
7 (1) 707053 107229 
191634 
7 (2) 424161 73551 
Severe 15 (F, 68) 
39 (1) 330027 52159 
102887 
2467 1232 
39 (2) 252573 44751 
41 (1) 285227 40809 
70733 41 (2) 111393 21975 
41 (3) 22780 3473 
71 (1) 2722 2550 
32925 
71 (2) 27529 8412 
71 (3) 114391 12003 
71 (4) 64427 8053 
16 (M, 75) 
44 (1) 393239 43502 
84714 
848 328 
44 (2) 249452 37010 
53 (1) 319869 36988 
93905 
53 (2) 390043 52473 
17 (M, 60) 
22 (1) 217292 25681 
88196 
972 393 
22 (2) 445077 57879 
36 (1) 579192 47906 
63325 36 (2) 77254 10672 
36 (3) 29979 2990 
18 (F, 62) 
8 (1) 268701 40873 
70530 
2142 938 
8 (2) 167760 26507 
30 (1) 339144 48349 
159879 30 (2) 248845 48291 
30 (3) 333632 56928 
19 (M, 56) 6 (1) 428221 69313 75128 1885 964 
Unproductive Pooled Pooled 270632 79463 88312 4826 1065 
 
Table S1. Statistics of BCR repertoire sequence data from healthy individuals, and COVID-19 patients. The 
Information about individuals in each cohort is shown. Detailed statistics of the processed data for productive BCRs 
are shown for read abundance, number of singletons, and number of unique sequences for all replicates and sampled 
time-points in each individual. For each individual, the number of lineages with more than two and ten unique 
sequences across all time points are shown in separate columns. Read statistics for unproductive receptors pooled 
from all individuals is shown separately. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5’-end primer Sequence (5’-3’) 
IGHV1 CCTCAGTGAAGGTCTCCTGCAAGG 
IGHV2 TCCTGCGCTGGTGAAACCCACACA 
IGHV3 GGTCCCTGAGACTCTCCTGTGCA 
IGHV4 TCGGAGACCCTGTCCCTCACCTGC 
IGHV5 CAGTCTGGAGCAGAGGTGAAA 
IGHV6 CCTGTGCCATCTCCGGGGACAGTG 
3’-end primer Sequence (5’-3’) 
CHG-R GCGCCTGAGTTCCACGACAC 
Table S2. List of primers used for PCR amplification of B-cell repertoires samples. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S3. Rare expanding BCRs shared among individuals. The list of rare progenitors of clonal lineages (i.e., with 
Ppost below the dashed line in Fig. 5) that exhibit lineage expansion in at least one individual is shown. These receptors are 
indicated by red diamonds in Fig. 5. The 34 rare expanding lineage progenitors shown here are shared among four to 12 
COVID-19 patients. 
IGHV gene IGHJ gene HCDR3 # ind. log34 𝑃post 
IGHV4-39 IGHJ3 CARLKRYYDSSGSPSAFDIW 12 -12.29 
IGHV6-1 IGHJ5 CARITFAVIPPW 11 -14.61 
IGHV4-61 IGHJ1 CARIGYDSSGYYYIFQHW 11 -12.81 
IGHV4-39 IGHJ5 CARQKMGSVTIFGVVMHDNWFDPW 11 -17.13 
IGHV4-39 IGHJ4 CARHVHMTWFEPSPGFDYW 11 -19.15 
IGHV4-30-4 IGHJ4 CARDRGLGVIENFDYW 11 -12.72 
IGHV6-1 IGHJ4 CARGGWGAPGSGRLFDYW 10 -14.45 
IGHV4-61 IGHJ4 CAREVGSYYDWRPDYW 10 -13.20 
IGHV4-59 IGHJ5 CARQDAWAYCGGDCYRGWFDPW 10 -15.24 
IGHV4-59 IGHJ3 CARDHPYGDPRGAFDIW 10 -12.92 
IGHV4-4 IGHJ5 CARGVAGEYWNDGKIRDFNWFDPW 10 -22.40 
IGHV2-5 IGHJ4 CAHSIKPRRSGYCSGGSCYHFDYW 10 -17.44 
IGHV4-59 IGHJ4 CARSRSGGSCYSFPSWYFDYW 9 -14.35 
IGHV4-4 IGHJ6 CATLSRRAAAGTRDYYGMDVW 9 -14.30 
IGHV4-34 IGHJ6 CARGQRSGACSGGSCVYYYGMDVW 9 -15.12 
IGHV4-34 IGHJ6 CARGDDNYCTYSYGYGRLNRYYYYGMDVW 9 -22.99 
IGHV2-70 IGHJ4 CARSYGTTVVTRAFDYW 9 -15.66 
IGHV4-59 IGHJ4 CARQRKATVVTAILFDYW 8 -14.92 
IGHV4-59 IGHJ4 CARHALGYFDWLNEGYFDYW 8 -15.36 
IGHV4-39 IGHJ6 CARQPVLRYFDWLPWFGGMDVW 8 -14.45 
IGHV4-39 IGHJ4 CVRSRAERYFDWTKLDAHVKPYYFDYW 8 -29.01 
IGHV4-34 IGHJ5 CARESYAYTLTRGSTWFDPW 8 -16.22 
IGHV4-34 IGHJ5 CAMGFHCSGGSCYDGVLGSW 8 -21.22 
IGHV4-34 IGHJ3 CARGRRPVVVPAAGPAGRAFDIW 8 -15.62 
IGHV4-34 IGHJ2 CARLNGWGIVVVIAIPRKNWYFDLW 8 -18.05 
IGHV3-48 IGHJ4 CARDKYCSSTSCLHGRHYFDYW 8 -14.97 
IGHV2-5 IGHJ4 CAQSNDVLRYFDWLYKMRGFDYW 8 -19.88 
IGHV6-1 IGHJ6 CARGRMVPYSSSWTTLYYYYGMDVW 7 -16.47 
IGHV4-59 IGHJ4 CARHRRLGLISDSSVDYW 7 -17.39 
IGHV4-59 IGHJ4 CARGDVEMATIKSGGPFYHFDYW 7 -22.78 
IGHV4-39 IGHJ3 CARRGRKLLPVAGTIDAFDIW 7 -15.83 
IGHV4-34 IGHJ6 CARARTVTTFFLGVRVGMDVW 6 -17.99 
IGHV4-34 IGHJ4 CARAIQSQHIVVVIAIPRPFYYFDYW 6 -18.23 
IGHV4-28 IGHJ4 CATGFSGYSSSWYDKPLLEVEHAGPYFDYW 4 -30.77 
